291 related articles for article (PubMed ID: 37874628)
1. Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic.
Lyskjær I; Iisager L; Axelsen CT; Nielsen TK; Dyrskjøt L; Fristrup N
Clin Cancer Res; 2024 Feb; 30(4):663-672. PubMed ID: 37874628
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.
Rosellini M; Marchetti A; Mollica V; Rizzo A; Santoni M; Massari F
Nat Rev Urol; 2023 Mar; 20(3):133-157. PubMed ID: 36414800
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Biomarkers in the Management of Renal Cell Carcinoma.
Reese S; Calderon L; Khaleel S; Hakimi AA
Urol Clin North Am; 2023 Feb; 50(1):151-159. PubMed ID: 36424079
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
Martinez Chanza N; Tripathi A; Harshman LC
Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
[TBL] [Abstract][Full Text] [Related]
5. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.
Speed JM; Trinh QD; Choueiri TK; Sun M
Curr Urol Rep; 2017 Feb; 18(2):15. PubMed ID: 28213859
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of renal cancer: new horizons.
Greef B; Eisen T
Br J Cancer; 2016 Aug; 115(5):505-16. PubMed ID: 27490806
[TBL] [Abstract][Full Text] [Related]
7. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
Zibelman M; Plimack ER
J Natl Compr Canc Netw; 2017 Jun; 15(6):841-847. PubMed ID: 28596263
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
9. May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials.
Messina C; Zanardi E; Boccardo F
Anticancer Agents Med Chem; 2017; 17(12):1633-1643. PubMed ID: 28270065
[TBL] [Abstract][Full Text] [Related]
10. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
11. The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell cancer.
Ramsey S
Mol Diagn Ther; 2009; 13(5):277-81. PubMed ID: 19791832
[TBL] [Abstract][Full Text] [Related]
12. [Personalised medicine in renal cell tumours].
Junker K; Zeuschner P
Aktuelle Urol; 2019 Sep; 50(5):513-523. PubMed ID: 31167243
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in renal cell carcinoma.
Volpe A; Patard JJ
World J Urol; 2010 Jun; 28(3):319-27. PubMed ID: 20364259
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
15. The role of adjuvant immunotherapy in renal cell carcinoma.
Mulders PF; De Mulder PH
Curr Urol Rep; 2002 Feb; 3(1):44-9. PubMed ID: 12084219
[TBL] [Abstract][Full Text] [Related]
16. Renal cell carcinoma: current status and emerging therapies.
Nelson EC; Evans CP; Lara PN
Cancer Treat Rev; 2007 May; 33(3):299-313. PubMed ID: 17329029
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy for advanced renal cell carcinoma.
Meissner MA; McCormick BZ; Karam JA; Wood CG
Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
Guida M; Colucci G
Ann Oncol; 2007 Jun; 18 Suppl 6():vi149-52. PubMed ID: 17591810
[TBL] [Abstract][Full Text] [Related]
19. Renal cell carcinoma: basic biology and clinical behavior.
Franklin JR; Figlin R; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):208-15. PubMed ID: 8946619
[TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
